Association analysis of A20 eccDNA mRNA in B-cell lymphoma cells and its application in the study of platinum nanoenzyme therapy mechanism

Diffuse large B-cell lymphoma (DLBCL) is a common but difficult to treat type of non Hodgkin lymphoma. At present, platinum nanoparticles with enzyme mimicking activity - platinum nanoenzymes - have been well applied in the treatment of DLBCL disease, but the molecular mechanism of their treatment is still unclear and there is a certain degree of drug resistance. Extrachromosomal circular DNA (eccDNA) elements have been shown to be widely present in eukaryotic genomes and associated with drug resistance. However, the characteristics and biological functions of eccDNA in DLBCL are still unclear. In this study, we investigated the transcriptome changes, eccDNA feature changes, and potential biological functions of eccDNA before and after treatment of A20 cells with platinum nanoenzymes. We identified a total of 7248 eccDNAs, most of which are distributed on each chromosome of mice within 1000bp in size. Bioinformatics analysis showed the detection of 5 important genes, among which Adgre1 was associated with multiple eccDNA differentially expressed genes in subsequent analysis, and may promote tumor progression through multiple mechanisms in drug therapy for cancer. We found that overexpression of Adgre1 may be an important factor in reducing the effect of platinum nanoenzyme treatment on diffuse large B-cell lymphoma cell line A20.